We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
- Authors
Dang, Nam H; Hagemeister, Fredrick B; Pro, Barbara; McLaughlin, Peter; Romaguera, Jorge E; Jones, Dan; Samuels, Barry; Samaniego, Felipe; Younes, Anas; Wang, Michael; Goy, Andre; Rodriguez, Maria A; Walker, Pamela L; Arredondo, Yolanda; Tong, Ann T; Fayad, Luis
- Abstract
Denileukin diftitox is a fusion protein combining diphtheria toxin and interleukin-2 (IL-2) that targets tumor cells expressing the IL-2 receptor. Its efficacy has been shown in CD25+ cutaneous T-cell lymphoma, but not in B-cell non-Hodgkin's lymphoma (NHL). A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Vol 22, Issue 20, p4095
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2004.03.071